FIT (Fracture Intervention Trial) Cost, Cost-Effectiveness, and Health-Economic Implications

By
Published Updated Last reviewed
Prescription access and medication affordability image for FIT (Fracture Intervention Trial) Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

  • Trial: Fracture Intervention Trial (FIT), vertebral fracture arm
  • N: 4,432 postmenopausal women with low femoral-neck BMD
  • Intervention: Alendronate 5 mg/day (increased to 10 mg/day after 24 months) vs placebo
  • Duration: Median 4.2 years (FIT-1 vertebral fracture arm) and 4.2 years (FIT-2)
  • Primary endpoint: Radiographically confirmed new vertebral fractures
  • Key result: 47% relative risk reduction in morphometric vertebral fractures (Black et al., 1996; Cummings et al., 1998)
  • Economic context: Brand alendronate (Fosamax) launched at ~$70/month; generic versions available since 2008 at $4-15/month

Why Health Economics Matter for a Generic Drug

Most clinicians think of alendronate as "cheap and proven." That framing is correct today but obscures two decades of economic debate that shaped prescribing guidelines, insurance formularies, and patient access worldwide. The FIT data served as the clinical backbone for every major cost-effectiveness model of oral bisphosphonate therapy published between 1998 and 2012.

Understanding these models matters because they still influence three active questions: which patients genuinely benefit enough to justify even a low-cost drug's side-effect profile, how payers set FRAX-based treatment thresholds, and whether newer (expensive) agents like denosumab or romosozumab offer incremental value over a baseline bisphosphonate strategy.

The Clinical Effect That Drove the Models

The FIT vertebral fracture arm enrolled women with existing vertebral deformities and femoral-neck T-scores of -1.6 or below. Over 36 months, alendronate reduced the risk of new morphometric vertebral fractures by 47% (RR 0.53 to 95% CI 0.41-0.68) and clinical vertebral fractures by 55%. Hip fracture risk fell by 51% in the same cohort, though the trial was not powered for hip fracture as a primary outcome. These absolute risk reductions, not just relative numbers, became the efficacy inputs for subsequent Markov and microsimulation models.

FIT-2 (Cummings et al., 1998) studied women with low BMD but no prevalent vertebral fracture. Results showed a statistically significant reduction in clinical fractures only in the subgroup with femoral-neck T-scores at or below -2.5. This subgroup analysis became the economic pivot point: models consistently found alendronate cost-effective in women meeting WHO osteoporosis criteria but marginal or unfavorable in osteopenia without additional risk factors.

Published Cost-Effectiveness Analyses Based on FIT

Several research groups built formal economic models using FIT efficacy data. The table below synthesizes the key published analyses. All costs are inflated to approximate 2024 USD where the original currency was reported in earlier dollars.

| Study | Model Type | Population | Drug Cost Assumed | ICER ($/QALY) | Threshold Met? | |---|---|---|---|---|---| | Schousboe et al., 2005 | Markov | 65 y women, T-score ≤ -2.5 | Brand (~$75/mo) | $28,000-$45,000 | Yes (at $50K) | | Kanis et al., 2008 (IOF) | Microsimulation | 70 y women, prior fracture | Brand (~$70/mo) | $18,000-$32,000 | Yes (at $50K) | | Nayak et al., 2012 | Markov, post-generic | 65 y women, T-score ≤ -2.5 | Generic (~$12/mo) | $4,200-$11,500 | Yes (at $50K) | | Hiligsmann et al., 2009 | Markov (Belgian payer) | 60-80 y women, various BMD | Brand equivalent | €12,700-€38,400 | Yes (at €40K) | | Strom et al., 2007 (NICE) | Markov (UK NHS) | 70 y women, T-score ≤ -2.5 | UK generic pricing | £5,200-£12,000 | Yes (at £20K) |

Three patterns emerge from these analyses.

First, every published model found alendronate cost-effective in women aged 65 or older with BMD-defined osteoporosis or a prior fragility fracture. The drug clears the $50,000/QALY threshold used by most US payers under virtually every scenario tested. At generic pricing, it clears $20,000/QALY in high-risk groups.

Second, age is a powerful modifier. Models consistently showed worsening cost-effectiveness in younger women (under 55) without prevalent fractures. The short-term fracture probability is simply too low for the drug to generate enough avoided events to offset costs and disutility from side effects and monitoring.

Third, adherence assumptions dramatically shift the numbers. FIT achieved ~95% adherence through protocol-driven follow-up. Real-world adherence to oral bisphosphonates hovers near 50% at 12 months. When models incorporated 50% persistence, ICERs roughly doubled, pushing brand-price alendronate above $50,000/QALY in some moderate-risk subgroups.

List Price vs. Net Price: What Patients Actually Pay

The economic story of alendronate splits cleanly at 2008, when Merck's Fosamax patent expired. Before generic entry, a year of brand alendronate cost patients or payers roughly $900-$1,100. After generic availability, cash prices dropped to $50-$180 per year at retail pharmacies, and large-volume programs (Walmart $4 generics, Mark Cuban Cost Plus Drugs) brought the annual cost below $50 in many markets.

This price collapse matters for patient-level decision-making. A woman with osteopenia and a 10-year major osteoporotic fracture probability of 12% (below most treatment thresholds) might reasonably decide that $4/month is worth the modest absolute risk reduction even if formal QALY models call the ICER "marginal." Cost-effectiveness thresholds are population-level policy tools. Individual willingness-to-pay calculations can diverge from them.

Current Medicare Part D coverage treats generic alendronate as a Tier 1 drug with typical copays of $0-$10/month. Most commercial plans similarly place it at the lowest cost-sharing tier. The access barrier for alendronate in 2026 is not financial, it is awareness, diagnosis, and prescriber inertia.

FRAX Integration and Treatment Thresholds

The FRAX calculator operationalized FIT-derived data into clinical practice. The US National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) set pharmacologic treatment thresholds at a 10-year hip fracture probability of 3% or a 10-year major osteoporotic fracture probability of 20%. These thresholds were explicitly calibrated so that treatment with a generic bisphosphonate would fall below $60,000/QALY for the typical patient meeting criteria.

This calibration means the FRAX threshold and the alendronate cost-effectiveness data are not independent inputs. They were designed together. Clinicians applying FRAX thresholds are implicitly applying FIT-derived economic logic whether they recognize it or not.

Alendronate as the Economic Comparator for Newer Agents

Every health-economic evaluation of denosumab, romosozumab, and zoledronic acid uses oral alendronate as the reference comparator. This is a direct consequence of FIT establishing the efficacy baseline. When the FDA approved romosozumab (Evenity) in 2019 at a list price exceeding $22,000/year, cost-effectiveness analyses asked whether the incremental fracture reduction over alendronate justified a 100-fold cost increase.

Published models suggest romosozumab is cost-effective only in very-high-risk patients (T-score < -3.0 with prior vertebral fracture) when followed by alendronate maintenance. For the broader osteoporosis population, oral alendronate remains the dominant strategy on cost-effectiveness grounds.

Denosumab (Prolia), priced at approximately $1,800/year after negotiated discounts, shows ICERs of $40,000-$75,000/QALY versus generic alendronate depending on patient age and risk profile. It enters favorable territory mainly in patients who cannot tolerate oral bisphosphonates or who have very high fracture risk. The pending biosimilar entry for denosumab (expected 2025-2026) may shift this calculus.

Limitations of FIT-Based Economic Models

Several structural limitations affect all economic analyses built on FIT data.

Efficacy-effectiveness gap. FIT's protocol-driven adherence does not reflect community practice. Models that used FIT efficacy directly, without adjusting for real-world persistence, overestimate the value of alendronate. The best models applied adherence corrections from observational cohorts, but even these corrections carry uncertainty.

Utility estimates for fracture states. QALY calculations depend on how much quality of life a fracture removes. Different studies used different utility decrements for vertebral and hip fractures, ranging from 0.05 to 0.20 for clinical vertebral fractures and 0.15 to 0.30 for hip fractures. This variation alone can shift an ICER by 40-60%.

Time horizon sensitivity. Most models used lifetime horizons with Markov cycling. Short-horizon models (5 years) produced less favorable results because bisphosphonate benefits accrue over time while costs are front-loaded. The choice of time horizon is a modeling judgment, not a clinical fact.

Indirect cost omission. Many early models captured only direct medical costs (drug, monitoring, fracture treatment). Lost productivity, caregiver burden, and long-term nursing home costs from hip fractures were inconsistently included. Models that incorporated indirect costs found alendronate even more cost-effective because avoided hip fractures prevent the most expensive downstream care.

Single-trial dependency. While FIT was large and well-conducted, nearly all alendronate economic models trace back to its efficacy estimates. Independent replication of those specific magnitudes in a similarly rigorous RCT does not exist for the vertebral fracture endpoint, though meta-analyses of smaller trials are broadly consistent.

What This Means for Patients in 2026

For a postmenopausal woman with a T-score at or below -2.5, or anyone with a prior fragility fracture, generic alendronate represents one of the most cost-effective pharmaceutical interventions available in any therapeutic area. At $4-$15/month with established fracture reduction of 47% for vertebral and roughly 50% for hip fractures in high-risk groups, the value proposition is difficult to challenge on economic grounds.

The relevant patient-level questions are not about cost. They concern tolerability (esophageal irritation, musculoskeletal pain), convenience (weekly fasting-dose regimen), and whether the patient's actual fracture risk is high enough to warrant years of therapy. The economic analyses built on FIT confirm that once fracture risk crosses guideline thresholds, the financial argument for treatment is settled.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References